Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 31;14(12):e0227098.
doi: 10.1371/journal.pone.0227098. eCollection 2019.

Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts

Affiliations

Antibiotic saving effect of combination therapy through synergistic interactions between well-characterized chito-oligosaccharides and commercial antifungals against medically relevant yeasts

Monica Ganan et al. PLoS One. .

Abstract

Combination therapies can be a help to overcome resistance to current antifungals in humans. The combined activity of commercial antifungals and soluble and well-defined low molecular weight chitosan with average degrees of polymerization (DPn) of 17-62 (abbreviated C17 -C62) and fraction of acetylation (FA) of 0.15 against medically relevant yeast strains was studied. The minimal inhibitory concentration (MIC) of C32 varied greatly among strains, ranging from > 5000 μg mL-1 (Candida albicans and C. glabrata) to < 4.9 (C. tropicalis). A synergistic effect was observed between C32 and the different antifungals tested for most of the strains. Testing of several CHOS preparations indicated that the highest synergistic effects are obtained for fractions with a DPn in the 30-50 range. Pre-exposure to C32 enhanced the antifungal effect of fluconazole and amphotericin B. A concentration-dependent post-antifungal effect conserved even 24 h after C32 removal was observed. The combination of C32 and commercial antifungals together or as part of a sequential therapy opens new therapeutic perspectives for treating yeast infections in humans.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
Inhibition of C. albicans (a, b) and C. guillermondii (c, d) when exposed to sub-inhibitory concentrations of CA and C32 at 0.25 x MIC (a, c) or MICC (b, d). The CA were applied at MICC, i.e. at concentrations that hardly inhibit the yeasts. The graphs show the amount of viable cells over time. Color coding is provided in the Figure. Standard deviations are omitted for clarity. Normally, these were between 0.1 to 0.5 Log CFU ml-1 units.
Fig 2
Fig 2
Sequential therapy time-kill curve for C. albicans (a) and C. guillermondii (b) in the presence of amphotericin B or fluconazole (concentration = 0.25 x MIC) after 12 h pre exposure to C32 (concentration = 0.25 x MIC). Color coding is provided in the Figure. Standard deviations are omitted for clarity. Normally, these were between 0.1 to 0.5 Log CFU ml-1 units.

Similar articles

Cited by

References

    1. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis. 2002;43(1):13–7. 10.1016/s0732-8893(02)00361-9 - DOI - PubMed
    1. Louie A, Kaw P, Banerjee P, Liu W, Chen G, Miller MH. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother. 2001;45(2):485–94. Epub 2001/02/13. 10.1128/AAC.45.2.485-494.2001 - DOI - PMC - PubMed
    1. Baddley J, Poppas P. Antifungal Combination Therapy. Drugs. 2005;65(11):1461–80. 10.2165/00003495-200565110-00002 - DOI - PubMed
    1. Uppuluri P, Nett J, Heitman J, Andes D. Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms. Antimicrob Agents Chemother. 2008;52(3):1127–32. 10.1128/AAC.01397-07 - DOI - PMC - PubMed
    1. Healey KR, Perlin DS. Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata. J Fungi. 2018;4(3):105 10.3390/jof4030105 . - DOI - PMC - PubMed

Publication types

MeSH terms